| VAN EIMEREN, T., A. ANTONINI, D. BERG, N. BOHNEN, R. CERAVOLO, A. DRZEZGA, G. HÖGLINGER, M. HIGUCHI, S. LEHERICY, S. LEWIS, O. MONCHI, P. NESTOR, M. ONDRUS, N. PAVESE, M.C. PERALTA, P. PICCINI, J.A. PINEDA-PARDO, Irena REKTOROVÁ and M. RODRÍGUEZ-OROZ. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. Elsevier, 2019, vol. 11, No 2019, p. 301-309. ISSN 2352-8729. Available from: https://dx.doi.org/10.1016/j.dadm.2019.01.011. |
Other formats:
BibTeX
LaTeX
RIS
@article{1642546,
author = {van Eimeren, T. and Antonini, A. and Berg, D. and Bohnen, N. and Ceravolo, R. and Drzezga, A. and Höglinger, G. and Higuchi, M. and Lehericy, S. and Lewis, S. and Monchi, O. and Nestor, P. and Ondrus, M. and Pavese, N. and Peralta, M.C. and Piccini, P. and PinedaandPardo, J.A. and Rektorová, Irena and RodríguezandOroz, M.},
article_number = {2019},
doi = {http://dx.doi.org/10.1016/j.dadm.2019.01.011},
keywords = {Biomarker; CDB; CBS; MRI;MSA},
language = {eng},
issn = {2352-8729},
journal = {Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring},
title = {Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System},
url = {https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.dadm.2019.01.011},
volume = {11},
year = {2019}
}
TY - JOUR
ID - 1642546
AU - van Eimeren, T. - Antonini, A. - Berg, D. - Bohnen, N. - Ceravolo, R. - Drzezga, A. - Höglinger, G. - Higuchi, M. - Lehericy, S. - Lewis, S. - Monchi, O. - Nestor, P. - Ondrus, M. - Pavese, N. - Peralta, M.C. - Piccini, P. - Pineda-Pardo, J.A. - Rektorová, Irena - Rodríguez-Oroz, M.
PY - 2019
TI - Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
VL - 11
IS - 2019
SP - 301-309
EP - 301-309
PB - Elsevier
SN - 23528729
KW - Biomarker
KW - CDB
KW - CBS
KW - MRI;MSA
UR - https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.dadm.2019.01.011
L2 - https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.dadm.2019.01.011
N2 - Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.
ER -
VAN EIMEREN, T., A. ANTONINI, D. BERG, N. BOHNEN, R. CERAVOLO, A. DRZEZGA, G. HÖGLINGER, M. HIGUCHI, S. LEHERICY, S. LEWIS, O. MONCHI, P. NESTOR, M. ONDRUS, N. PAVESE, M.C. PERALTA, P. PICCINI, J.A. PINEDA-PARDO, Irena REKTOROVÁ and M. RODRÍGUEZ-OROZ. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. \textit{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}. Elsevier, 2019, vol.~11, No~2019, p.~301-309. ISSN~2352-8729. Available from: https://dx.doi.org/10.1016/j.dadm.2019.01.011.
|
